Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics analysis

Neoplasia

Volumn 12, Issue 2, 2010, Pages 206-213

  Langenberg, Marlies H G ^a   Witteveen, Petronella O ^a   Lankheet, Nienke A G ^b   Roodhart, Jeanine M L ^a   Rosing, Hilde ^b   Van Den Heuvel, Ingeborg J G M ^a   Beijnen, Jos H ^b   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; VATALANIB;

ABSCESS; ACNE; ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHORDOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HEART MUSCLE ISCHEMIA; HEARTBURN; HUMAN; HYPERTENSION; HYPERTRICHOSIS; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; UTERINE CERVIX CARCINOMA; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 76749097152     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91864     Document Type: Article

References (36)

1. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357, 2666-2676.
4. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, and Mayer RJ (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22, 1201-1208.
5. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359, 1116-1127.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356, 115-124.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356, 125-134.
8. Ellis LM and Hicklin DJ (2008). VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 8, 579-591.
9. Carmeliet P (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl 3), 4-10.
10. Ferrara N, Gerber HP, and LeCouter J (2003). The biology of VEGF and its receptors. Nat Med 9, 669-676.
11. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, et al. (2005). Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16, 102-108.
12. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, and Fidler IJ (2003). Blockade of epidermal growth factor receptor signaling in tumor cells and tumorassociated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9, 1200-1210.
13. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, and Kerbel RS (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151, 1523-1530.
14. de Jong JS, van Diest PJ, van der Valk P, and Baak JP (1998). Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol 184, 44-52.
15. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, Drazan KE, Bucana CD, Hicklin DJ, and Ellis LM (2001). Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85, 584-589.
16. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De PS, Bianco AR, Mendelsohn J, and Tortora G (2000). Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6, 3739-3747.
17. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De FS, Melisi D, Benelli R, et al. (2008). Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14, 5069-5080.
18. Gelardi T, Caputo R, Damiano V, Daniele G, Pepe S, Ciardiello F, Lahn M, Bianco R, and Tortora G (2008). Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 99, 473-480.
19. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, et al. (2005). Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23, 2544-2555.
20. Sandler A and Herbst R (2006). Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12, 4421s-4425s.
21. Hainsworth JD, Spigel DR, Sosman JA, Burris HA III, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM, et al. (2007). Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/ imatinib: a phase I/II trial. Clin Genitourin Cancer 5, 427-432.
22. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, and Greco FA (2007). Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 25, 1747-1752.
23. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, et al. (2008). A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 14, 7878-7883.
24. Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K, Bodoky G, Borner M, Laurent D, and Jacques C (2005). A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 23, 16S; [Part I of II; Abstract ASCO 2005].
25. Kohne C, Bajetta E, Lin E, Valle JW, Van Cutsem E, Hecht JR, Moore M, Germond CJ, Meinhardt G, and Jacques C (2007). Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. J Clin Oncol 25, 18S; [Abstract ASCO 2007].
26. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, et al. (2009). Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360, 563-572.
27. Staal S, O'Connell MJ, and Allegra CJ (2009). The marriage of growth factor inhibitors and chemotherapy: bliss or bust? J Clin Oncol 27, 1545-1548.
28. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, and Steward WP (2005). Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23, 4162-4171.
29. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, et al. (2000). Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18, 904-914.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92, 205-216.
31. Duda DG, Cohen KS, Scadden DT, and Jain RK (2007). A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2, 805-810.
32. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, and O'Dwyer PJ (2006). Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24, 1363-1369.
33. Verheul HM and Pinedo HM (2007). Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7, 475-485.
34. Roodhart JM, Langenberg MH, Witteveen E, and Voest EE (2008). The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3, 132-143.
35. Beerepoot LV, Mehra N, Vermaat JSP, Zonnenberg BA, Gebbink MFGB, and Voest EE (2004). Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15, 139-145.
36. Mehra N, Penning M, Maas J, Beerepoot LV, van DN, van Gils CH, Giles RH, and Voest EE (2006). Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 12, 4859-4866.